文摘
摘要目的:描述的临床特征的急性阶段anti-NMDAR脑炎(NMDARe)相似之处与精神分裂症谱系障碍(SCZ)和预测cognitive-psychiatric结果的因素。
背景:NMDARe与拖延相关症状在急性阶段,并不是众所周知的。
设计/方法:在这个前瞻性观察性研究中,患者在急性期NMDARe接受3访问(V1,研究入境;V2, 6个月;V3, 12个月),包括全面的神经精神评估在医院诊所,巴塞罗那。SCZ病人和健康的参与者(HC)进行了类似的评估。线性混合效应模型为评估纵向差异的措施。
结果:28 NMDARe, 27 SCZ, 27 HC招募。虽然,V1(中位数为4个月(IQR 3 - 7)从疾病发作),许多急性期NMDARe解决(急性期症状中位数5夫人(IQR 4 - 5)vsV1夫人[1 - 2];p < 0.0001), 89%的患者显示赤字≥1认知领域(CD)。在NMDARe, 15/22(68%)的CD变量在V1受损,而只有8/22(36%)的改变在V3 (p = 0.016)。在SCZ, 11/22(50%)的变量(所有与NMDARe共享)在V1,受损没有变化V3。两个急性期NMDARe特性(减少意识;没有改进治疗前4周内)CD预测结果,和视觉空间的任务(V1串行偏见)显示,预测潜在的学习和记忆的结果。在V1,所有精神症状簇也改变NMDARe SCZ,但只有NMDARe随后改善(p = 0.031)。最伟大的NMDARe cognitive-psychiatric改进v2 v1之间发生。在这个区间,14% NMDARe患者会遇到了精神分裂症的诊断标准如果脑脊液抗体发现没有调查。
结论:急性NMDARe与稳定的cognitive-psychiatric症状精神分裂症,但只有NMDARe患者逐步改善,主要在v2 v1。这些研究结果非常重要,对临床试验NMDARe和建议,促使cognitive-psychosocial康复可能是有价值的。
披露:Guasp博士没有披露。Mireia罗莎爵床没有披露。基本上Munoz-Lopetegi没有披露。马丁斯博士的机构已经收到了来自皇家研究院研究支持祝您健康卡洛斯三世。马丁斯博士已经收到个人补偿的范围为0 - 499美元作为旅游与生原体和演讲酬金。马丁斯已经收到博士个人补偿的范围为0 - 499美元作为旅游与UCB谢礼。Armangue博士已经收到个人薪酬在500 - 4999美元的范围为在科学咨询服务或数据安全监测委员会生原体。博士的机构Armangue收到ISCIII-FEDER研究支持;pi18 - 00486和PI21/00316,珀里斯Generalitat加泰罗尼亚(SLT006/17/00362);Pablove基金会(689368),Fundacio Marato de TV3 (37 / C / 2021) Torrons目前基金会(PFNR0144), 2021年美国电力公司投资。 Gisela Sugranyes has nothing to disclose. Dr. Stein has nothing to disclose. Laia Prades has nothing to disclose. Ms. Arino has nothing to disclose. The institution of Jesús Planagumà has received research support from Spanish ministry of health/ISCIII. Dr. De la Serna has nothing to disclose. Dr. Escudero has nothing to disclose. Sara Llufriu has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Sara Llufriu has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Sara Llufriu has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merci. Sara Llufriu has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbot. Sara Llufriu has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Raquel Sánchez-Valle has nothing to disclose. Joan Santamaria, MD has nothing to disclose. The institution of Albert Compte has received research support from Instituto de Salud Carlos III. The institution of Albert Compte has received research support from La Caixa Foundation. The institution of Albert Compte has received research support from Ministerio de Ciencia e Innovación. Josefina Castro-Fornieles has nothing to disclose. Dr. Dalmau has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astellas Research Institute of America. Dr. Dalmau has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen Research & Development . Dr. Dalmau has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Academy of Neurology. An immediate family member of Dr. Dalmau has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Dalmau has received research support from Sage Therapeutics. The institution of Dr. Dalmau has received research support from Edmond J.Safra Foundation . The institution of Dr. Dalmau has received research support from La Caixa Foundation. The institution of Dr. Dalmau has received research support from Spanish Ministry of Health (ISCIII). The institution of Dr. Dalmau has received research support from Euroimmun, Inc. Dr. Dalmau has received intellectual property interests from a discovery or technology relating to health care. An immediate family member of Dr. Dalmau has received intellectual property interests from a discovery or technology relating to health care. Dr. Dalmau has received intellectual property interests from a discovery or technology relating to health care. An immediate family member of Dr. Dalmau has received intellectual property interests from a discovery or technology relating to health care. Dr. Dalmau has received publishing royalties from a publication relating to health care. Dr. Dalmau has received publishing royalties from a publication relating to health care. Dr. Dalmau has received publishing royalties from a publication relating to health care.
